WAKEFIELD, Mass., Oct. 26, 2021 – PRESS RELEASE – Curaleaf Holdings Inc., a leading international provider of consumer products in cannabis, announced that its initial batches of New York whole flower have cleared testing by third-party labs and that sales of three initial strains will begin Oct. 26 in the company’s Newburgh location and Oct. 27 in Curaleaf’s Carle Place, Forest Hills and Plattsburgh dispensaries.
“Our patients have been waiting a long time for this day and we couldn’t be happier to be able to deliver whole flower product to all four of our New York locations in the next day or so and to the majority of our wholesale partners within the month,” Curaleaf CEO Joe Bayern said. “Fortunately, we have been preparing for this moment and we are more than ready with plenty of product for all our New York locations. We are grateful to Gov. Hochul and the OCM [Office of Cannabis Management] for moving this forward so quickly, and we look forward to robust sales and happy customers. We appreciate the patience and loyalty of all our patients as we worked toward this milestone.”
Prior to this month, cannabis was only available to New York patients in ground form, a source of frustration for many patients who prefer the plant’s medicinal applications in its purest and most natural format.
Curaleaf whole flower will also be available to the majority of the company’s wholesale partners in the state by the end of the month, ensuring that the company maintains its position as the New York market leader and its product will be available throughout the state.